10x Genomics, Inc.
10x Genomics, Inc. (Nasdaq: TXG) is a life sciences technology company providing integrated research tools to analyze biological systems at cellular and tissue scale. Its offerings combine instruments, consumables and software for single-cell, spatial and in situ analysis, serving academic, government,… From the company’s description.
Over the twelve months to Sep 30, 2026, 10x Genomics, Inc. reported revenue of $618.58M, down 3.6% from a year earlier, and a net loss of $67.08M. Its operating margin was −11.7%, and operations generated $99.70M in cash. In fiscal 2025, it reported revenue of $642.82M, up 5.2% from fiscal 2024, and a net loss of $43.54M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What 10x Genomics, Inc. does
In the company’s own words
10x Genomics, Inc. (Nasdaq: TXG) is a life sciences technology company providing integrated research tools to analyze biological systems at cellular and tissue scale. Its offerings combine instruments, consumables and software for single-cell, spatial and in situ analysis, serving academic, government, biopharmaceutical, biotechnology and other life sciences research institutions. The Chromium platform supports high-throughput single-cell and multiomic analysis; Visium maps molecular information across tissue sections; and Xenium detects RNA targets in place within tissue. Its software supports experiment planning, data processing, visualization and exploration. The company operates as one business and reports no separate operating segments in the described business overview. It sells directly in North America and certain European regions and uses distributors in other markets, reaching customers in more than 50 countries. In 2025, revenue was $642.8 million, and the company had sold 8,046 instruments since its first product launch in 2015. Its product brands include Chromium, Visium and Xenium; the QuantumScale kits joined its portfolio through the 2025 acquisition of Scale Biosciences. Its website is https://www.10xgenomics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- PLEASANTON, CA
- Fiscal year end
- December
- CIK
- 1770787
- SIC
- 3826
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns 10x Genomics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in 10x Genomics, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · 10x Genomics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do 10x Genomics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of 10x Genomics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in 10x Genomics, Inc.'s last four quarterly filings that the numbers alone won't show?”